FOSL1 Controls the Assembly of Endothelial Cells into Capillary Tubes by Direct Repression of αv and β3 Integrin Transcription

REFERENCES

• Malinin NL, Pluskota E, Byzova TV. 2012. Integrin signaling in vascular function. Curr. Opin. Hematol. 19:206–211.
   PubMedGoogle Scholar
• Bader BL, Rayburn H, Crowley D, Hynes RO. 1998. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95:507–519.
   PubMed Web of Science ®Google Scholar
• Drake CJ, Cheresh DA, Little CD. 1995. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci. 108:2655–2661.
   PubMed Web of Science ®Google Scholar
• Stupack DG, Cheresh DA. 2004. Integrins and angiogenesis. Curr. Top. Dev. Biol. 64:207–238.
   PubMed Web of Science ®Google Scholar
• Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. 1999. Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 18:882–892.
   PubMed Web of Science ®Google Scholar
• Borges E, Jan Y, Ruoslahti E. 2000. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J. Biol. Chem. 275:39867–39873.
   PubMed Web of Science ®Google Scholar
• Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. 2006. Integrin signaling is critical for pathological angiogenesis. J. Exp. Med. 203:2495–2507.
   PubMed Web of Science ®Google Scholar
• Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. 2007. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ. Res. 101:570–580.
   PubMed Web of Science ®Google Scholar
• Serini G, Napione L, Bussolino F. 2008. Integrins team up with tyrosine kinase receptors and plexins to control angiogenesis. Curr. Opin. Hematol. 15:235–242.
   PubMed Web of Science ®Google Scholar
• Galvagni F, Pennacchini S, Salameh A, Rocchigiani M, Neri F, Orlandini M, Petraglia F, Gotta S, Sardone GL, Matteucci G, Terstappen GC, Oliviero S. 2010. Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. Circ. Res. 106:1839–1848.
   PubMedGoogle Scholar
• Schreiber M, Wang ZQ, Jochum W, Fetka I, Elliott C, Wagner EF. 2000. Placental vascularisation requires the AP-1 component Fra1. Development 127:4937–4948.
   PubMedGoogle Scholar
• Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB. 2007. Deciphering AP-1 function in tumorigenesis: Fra-ternizing on target promoters. Cell Cycle 6:2633–2639.
   PubMed Web of Science ®Google Scholar
• Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M. 1995. Transcriptional activation of the Fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol. Cell. Biol. 15:3748–3758.
   PubMedGoogle Scholar
• Zippo A, De Robertis A, Serafini R, Oliviero S. 2007. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat. Cell Biol. 9:932–944.
   PubMed Web of Science ®Google Scholar
• Zippo A, Serafini R, Rocchigiani M, Pennacchini S, Krepelova A, Oliviero S. 2009. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 138:1122–1136.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Okuno H, Yoshida T, Endo T, Nishina H, Iba H. 1991. Difference in transcriptional regulatory function between c-Fos and Fra-2. Nucleic Acids Res. 19:5537–5542.
   PubMedGoogle Scholar
• Groskopf JC, Linzer DI. 1994. Characterization of a delayed early serum response region. Mol. Cell. Biol. 14:6013–6020.
   PubMedGoogle Scholar
• Welter JF, Crish JF, Agarwal C, Eckert RL. 1995. Fos-related antigen (Fra-1), junB, and junD activate human involucrin promoter transcription by binding to proximal and distal AP1 sites to mediate phorbol ester effects on promoter activity. J. Biol. Chem. 270:12614–12622.
   PubMed Web of Science ®Google Scholar
• Talotta F, Mega T, Bossis G, Casalino L, Basbous J, Jariel-Encontre I, Piechaczyk M, Verde P. 2010. Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein. Oncogene 29:4732–4740.
   PubMedGoogle Scholar
• Yoshioka K, Deng T, Cavigelli M, Karin M. 1995. Antitumor promotion by phenolic antioxidants: inhibition of AP-1 activity through induction of Fra expression. Proc. Natl. Acad. Sci. U. S. A. 92:4972–4976.
   PubMed Web of Science ®Google Scholar
• Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E. 1998. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol. Cell. Biol. 18:7095–7105.
   PubMed Web of Science ®Google Scholar
• Tkach V, Tulchinsky E, Lukanidin E, Vinson C, Bock E, Berezin V. 2003. Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. Oncogene 22:5045–5054.
   PubMed Web of Science ®Google Scholar
• Casalino L, Bakiri L, Talotta F, Weitzman JB, Fusco A, Yaniv M, Verde P. 2007. Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J. 26:1878–1890.
   PubMedGoogle Scholar
• Salameh A, Galvagni F, Anselmi F, De Clemente C, Orlandini M, Oliviero S. 2010. Growth factor stimulation induces cell survival by c-Jun. ATF2-dependent activation of Bcl-XL. J. Biol. Chem. 285:23096–23104.
   PubMedGoogle Scholar
• Takagi J, Petre BM, Walz T, Springer TA. 2002. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110:599–611.
   PubMed Web of Science ®Google Scholar
• Galvagni F, Lestingi M, Cartocci E, Oliviero S. 1997. Serum response factor and protein-mediated DNA bending contribute to transcription of the dystrophin muscle-specific promoter. Mol. Cell. Biol. 17:1731–1743.
   PubMedGoogle Scholar
• Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. 2005. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 106:3423–3431.
   PubMedGoogle Scholar
• Ory DS, Neugeboren BA, Mulligan RC. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U. S. A. 93:11400–11406.
   PubMed Web of Science ®Google Scholar
• Orlandini M, Nucciotti S, Galvagni F, Bardelli M, Rocchigiani M, Petraglia F, Oliviero S. 2008. Morphogenesis of human endothelial cells is inhibited by DAB2 via Src. FEBS Lett. 582:2542–2548.
   PubMedGoogle Scholar
• Galvagni F, Cantini M, Oliviero S. 2002. The utrophin gene is transcriptionally up-regulated in regenerating muscle. J. Biol. Chem. 277:19106–19113.
   PubMed Web of Science ®Google Scholar
• Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O. 2003. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. 31:334–341.
   PubMed Web of Science ®Google Scholar
• Kouskouti A, Talianidis I. 2005. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J. 24:347–357.
   PubMedGoogle Scholar
• Zippo A, De Robertis A, Bardelli M, Galvagni F, Oliviero S. 2004. Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103:4536–4544.
   PubMed Web of Science ®Google Scholar
• Guerrini L, Casalino L, Corti A, Blasi F. 1996. NF-kappa B-mediated regulation of urokinase gene expression by PMA and TNF-alpha in human A549 cells. FEBS Lett. 393:69–73.
   PubMedGoogle Scholar
• Lakka SS, Bhattacharya A, Mohanam S, Boyd D, Rao JS. 2001. Regulation of the uPA gene in various grades of human glioma cells. Int. J. Oncol. 18:71–79.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Lakka SS, Mohanam S, Boyd D, Rao JS. 2001. Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin. Cancer Res. 7:267–276.
   PubMedGoogle Scholar
• Jamaluddin MS. 2006. Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1. Biochem. Biophys. Res. Commun. 348:618–627.
   PubMedGoogle Scholar
• Kent LN, Rumi MA, Kubota K, Lee DS, Soares MJ. 2011. FOSL1 is integral to establishing the maternal-fetal interface. Mol. Cell. Biol. 31:4801–4813.
   PubMed Web of Science ®Google Scholar
• Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, Kessler H. 1999. N-Methylated cyclic RGD peptides as highly active and selective αVβ3 integrin antagonists. J. Med. Chem. 42:3033–3040.
   PubMed Web of Science ®Google Scholar
• Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov B, Saxel H, Kel AE, Wingender E. 2006. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34:D108–110.
   PubMed Web of Science ®Google Scholar
• Chamboredon S, Briggs J, Vial E, Hurault J, Galvagni F, Oliviero S, Bos T, Castellazzi M. 2003. v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3. Oncogene 22:4047–4061.
   PubMedGoogle Scholar
• Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL. 2001. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U. S. A. 98:4510–4515.
   PubMed Web of Science ®Google Scholar
• Wu J, Iwata F, Grass JA, Osborne CS, Elnitski L, Fraser P, Ohneda O, Yamamoto M, Bresnick EH. 2005. Molecular determinants of NOTCH4 transcription in vascular endothelium. Mol. Cell. Biol. 25:1458–1474.
   PubMedGoogle Scholar
• Snyder RC, Ray R, Blume S, Miller DM. 1991. Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry 30:4290–4297.
   PubMed Web of Science ®Google Scholar
• Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV, Rohr J. 2003. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry 42:8313–8324.
   PubMed Web of Science ®Google Scholar
• Berrier AL, Yamada KM. 2007. Cell-matrix adhesion. J. Cell. Physiol. 213:565–573.
   PubMed Web of Science ®Google Scholar
• Galvagni F, Cartocci E, Oliviero S. 1998. The dystrophin promoter is negatively regulated by YY1 in undifferentiated muscle cells. J. Biol. Chem. 273:33708–33713.
   PubMedGoogle Scholar
• Luo YP, Zhou H, Krueger J, Kaplan C, Liao D, Markowitz D, Liu C, Chen T, Chuang TH, Xiang R, Reisfeld RA. 2010. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene 29:662–673.
   PubMedGoogle Scholar